【TAIPEI, August 5, 2026】— Topmunnity Therapeutics Taiwan Limited today announced that it has been selected as one of the recipients of the Second Wistron Computing Power Donation Program, jointly organized by Wistron Corporation and Garage+.

 

This latest recognition follows Topmunnity's selection as a member of the NVIDIA Inception Program and participation in the Taipei-1 Project, jointly promoted by Taiwan's Ministry of Economic Affairs and NVIDIA. The consecutive selections underscore the industry's confidence in Topmunnity's capabilities in applying artificial intelligence to innovative drug discovery. Through the Wistron Computing Power Donation Program, Topmunnity will leverage high-performance GPU computing resources to strengthen its AI-powered antibody generation workflow, further enhancing drug discovery efficiency and reinforcing the Company's global competitiveness.

​

The Wistron Computing Power Donation Program provides high-performance GPU computing resources to promising AI startups, enabling them to accelerate technology validation and product development. The program also connects participating companies with industry partners, innovation ecosystems, and entrepreneurial resources to help strengthen the international competitiveness of Taiwan's startup ecosystem.

​

Topmunnity has long been committed to integrating artificial intelligence with biotechnology, continuously advancing its AI-driven drug discovery platform to compete at the forefront of global innovation. High-performance computing has become a critical foundation for next-generation AI drug development. The GPU resources provided through this program will further accelerate AI model development and validation, enhance computing performance, and strengthen Topmunnity's position among leading AI-driven drug discovery companies worldwide.

​

From joining the NVIDIA Inception Program, gaining access to Taipei-1, Taiwan's national AI supercomputing infrastructure, to now being selected for the Wistron Computing Power Donation Program, Topmunnity is grateful for the continued support from government and industry partners in advancing the Company's global development. By leveraging its proprietary AI-powered antibody design platform, Topmunnity aims to shorten drug development timelines, improve the precision of therapeutic design, and enhance the efficacy and safety of future medicines, ultimately accelerating the development of innovative therapies.

​

Looking ahead, Topmunnity will continue integrating artificial intelligence, high-performance computing, and biotechnology to build a more efficient and competitive drug discovery platform. The Company remains committed to becoming a global leader in TechBio innovation while delivering transformative therapies that improve the lives of patients worldwide.

 

​​​​​

​

Media Contact:

Andrea Yang

Finance Manager

info@topmunnity.com

+886-2-2301-2180

www.topmunnity.com